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In the present study, we assessed the relationship of serum insulin levels and three surrogate markers of recurrence, T stage,
PSA, and Gleason score, in men with localized prostate cancer. Participants in our study were found through urology and
radiation oncology clinics, and all eligible patients were asked to take part. All patients were asymptomatic and had been
initially diagnosed on the basis of rising PSA or abnormal physical examination. Histological conﬁrmation of diagnosis was
obtained for all subjects. Serum insulin levels were determined by chemoluminescent assay with a standard, commercially
available instrument. Patients were divided into three previously deﬁned risk groups: Low risk: PSA 410, stage 4T2a, or
Gleason grade 46. Medium risk: 10 5PSA 415, Gleason 7 or stage T2b. High risk: Gleason 47, tumour in seminal vesicle
biopsy, PSA 415 or stage T2c or T3. One hundred and sixty-three men with prostate cancer were studied. There was a
signiﬁcant increase in serum insulin with risk group (P=0.003, one way anova). Tukey’s multiple range test showed that the
insulin levels of high risk patients were signiﬁcantly higher than the insulin levels of medium and low risk patients (P=0.05) but
the insulin levels of medium and low risk patients were not signiﬁcantly different from one another. Multivariate linear
regression, with insulin as the dependent variable, Gleason score, PSA, and T stage (T1, T2, T3) as the independent variables,
was signiﬁcant overall (P50.001, r
2=0.120). Increased T stage was independently correlated with increased serum insulin levels
(P50.001). Gleason score was negatively, insigniﬁcantly correlated with serum insulin level (P=0.059). The positive correlation
of PSA and insulin level was not signiﬁcant (P=0.097). To assure normal distribution of insulin and PSA values, the regression
was repeated with log (insulin) as the dependent variable, log (PSA), T stage (T1, T2, T3), and Gleason score as independent
variables. The regression was signiﬁcant overall (P=0.002, r
2 =0.095). Increased T stage was independently correlated with
increased log (insulin level) (P=0.026). Gleason score was negatively, insigniﬁcantly correlated with log (insulin) level (P=0.728).
The positive correlation of log (PSA) and log (insulin) levels was signiﬁcant (P=0.010). The relationship between increased
insulin level and advanced tumour stage in prostate cancer we describe here is biologically quite plausible, since insulin is a
growth factor. Further studies may document whether serum insulin levels might be a useful biomarker of prostate cancer
stage.
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PSA, Gleason score, and stage at diagnosis are currently the most
reliable markers of prostate cancer prognosis and tumour aggres-
siveness (Oesterling et al, 1997). But urologists are actively
seeking additional biomarkers.
Many prostate cancers are quite indolent and may never cause a
problem, but it is now impossible to identify such tumours with
certainty. With more and better biomarkers, some older men
might be spared the rigors of radiation therapy and/or surgery,
and their complications.
Elevated insulin levels are associated with increased risk of pros-
tate cancer (Hsing et al, 2001) and increased risk of metastatic
disease in women with breast cancer (del Giudice et al, 1998;
Goodwin et al, 2000). Moreover, insulin is necessary for the growth
of prostate cancer cells in culture. For example, a special serum-
free deﬁned medium that can support short-term, long-term, and
clonal growth of the human prostatic carcinoma cell lines LNCaP,
DU 145, PC-3, and ALVA-31 must contain insulin (Hedlund and
Miller, 1994).
In a previous study (Lehrer et al, 2002), we measured insulin
levels in men with prostate cancer. We found that increased serum
insulin levels were associated with increased risk of recurrence. We
determined risk of recurrence by dividing the patients into
previously deﬁned risk groups (Stock et al, 2000), consisting of
three parameters: prostate speciﬁc antigen (PSA) level, tumour
stage, and Gleason score. We have now collected a larger patient
sample and have performed multivariate analysis to ascertain which
of the three parameters are most related to insulin level.
METHODS
Participants in our study were found through urology and radia-
tion oncology clinics, and all eligible patients were asked to take
part. All patients had been initially diagnosed on the basis of rising
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www.bjcancer.comof diagnosis was obtained for all subjects. All participants gave
informed consent. All staging was clinical, because almost all the
patients were to receive I-125 seed implant.
We studied men referred for treatment of localized prostate
cancer. In our treatment protocol, patients are divided into three
risk groups (Stock et al, 2000).
Low risk
PSA 410, stage 4T2a, or Gleason grade 46. These patients are
treated with a radioactive implant.
Medium risk
10 5PSA 415, Gleason 7 or stage T2b. These patients are treated
with 3 months combined hormonal therapy followed by an
implant.
High risk
Gleason 47, tumour in seminal vesicle biopsy, PSA 415 or stage
T2c or T3. These patients are treated with 3 months’ combined
hormonal therapy, an implant, and after 2 months’ break 6000 rads
with external beam radiotherapy.
Serum insulin levels were determined by chemoluminescent
assay with a standard, commercially available instrument (Immulite
Diagnostic Products Corporation, Los Angeles, CA, USA).
RESULTS
Patients studied: 163; 73 were low risk, 22 medium risk, and 68
high risk. The youngest was 46, the oldest 88, average age
67+8.2 (mean +s.d.).
There was a signiﬁcant increase in serum insulin with risk group
(P= 0.003, one-way anova, Figure 1). Tukey’s multiple range test
showed that the insulin levels of high risk patients were signiﬁ-
cantly higher than the insulin levels of medium and low risk
patients (P=0.05) but the insulin levels of medium and low risk
patients were not signiﬁcantly different from one another.
Multivariate linear regression, with insulin as the dependent
variable, Gleason score, PSA, and T stage (T1, T2, T3) as the inde-
pendent variables, was signiﬁcant overall (P50.001, r
2=0.120).
Increased T stage was independently correlated with increased
serum insulin level (P50.001). Gleason score was negatively, insig-
niﬁcantly correlated with serum insulin level (P=0.059). The
positive correlation of PSA and insulin level was not signiﬁcant
(P=0.097).
To assure normal distribution of insulin and PSA values, the
regression was repeated with log (insulin) as the dependent vari-
able, log (PSA), T stage (T1, T2, T3), and Gleason score as
independent variables. The regression was signiﬁcant overall
(P=0.002, r
2=0.095). Increased T stage was independently corre-
lated with increased log (insulin level) (P=0.026). Gleason score
was negatively, insigniﬁcantly correlated with log (insulin) level
(P=0.728). The positive correlation of log (PSA) and log (insulin)
levels was signiﬁcant (P=0.010).
DISCUSSION
One possible weakness in our study is the fact that serum insulin
levels were measured in the three treatment groups after therapy
had been completed. Therefore, it would be worthwhile in future
studies to measure serum insulin levels both before and after ther-
apy, in order to correct for possible error caused by the
differences in treatment delivered to the three risk groups.
Another possible weakness is the relatively smaller number of
cases in the intermediate risk group, when compared to the low
and high risk groups. Further larger studies should be done to
eliminate this weakness.
Data from epidemiological and biological research implicate
insulin-like growth factors I and II (IGF-I and IGF-II) in the regu-
lation of prostate epithelial cell proliferation, and in the
pathophysiology of prostate cancer (Pollak et al, 1998). But there
has been little investigation into the role insulin itself plays in pros-
tate cancer. Isolated epithelial cells of rat ventral prostate have
insulin receptors, and fasting increases their concentration (Carme-
na et al, 1986). But PA-III rat prostate adenocarcinoma cells have
no insulin receptor, though they do have speciﬁc binding sites for
IGF-I and II (Polychronakos et al, 1991).
One large epidemiologic study found an equivocal relationship
between diabetes mellitus and prostate cancer. In hundreds of
thousands of male respondents, the 1959–1972 Cancer Prevention
Study explored whether men with diabetes were more likely to
develop prostate cancer during a 13-year follow-up than men with-
out diabetes. After adjustment for factors associated with prostate
cancer in previous studies, little association was found between
diabetes at baseline and prostate cancer incidence. Men who had
diabetes mellitus for ﬁve or more years, however, had a higher inci-
dence of prostate cancer than did men without diabetes. But
among all study participants who were diagnosed with prostate
cancer, men with diabetes were only slightly more likely to die
from prostate cancer than were men without diabetes (Will et al,
1999).
The relationship between increased insulin level and advanced
tumour stage in prostate cancer we describe here is biologically
quite plausible, since insulin is a growth factor. Further studies
may document whether serum insulin level might be a useful


















Figure 1 Serum insulin (mIu ml
71) levels of men with prostate cancer.
Number of cases in each risk group is above the error bar. There was sig-
niﬁcant variation of insulin (P=0.003, one way anova). Tukey’s multiple
range test showed that the insulin levels of high risk patients were signifi-
cantly higher than the insulin levels of medium and low risk patients
(P=0.05) but the insulin levels of medium and low risk patients were not
signiﬁcantly different from one another. (The normal insulin range in our
laboratory is 6–27 mIu ml
71).
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